KI
RNAM

Kula Investments’s Avidity Biosciences RNAM Stock Holding History

Kula Investments’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$353K Buy
23,023
+5,065
+28% +$111K 0.09% 411
2022
Q4 		$398K Buy
+17,958
New +$268K 0.12% 290

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Kula Investments's RNAM Position: Q1 2023 in Review

Kula Investments increased its Avidity Biosciences (RNAM) stake by 28% in Q1 2023, buying an estimated $111K and bringing the position to 23,023 shares worth $353K. The position accounts for 0.09% of the portfolio, ranked #411.

Kula Investments first reported a position in RNAM in Q4 2022 and has held it in 2 quarters since. The position peaked at $398K in Q4 2022. 139 funds tracked by Wall St. Rank hold RNAM as of Q1 2023.

  • Kula Investments held 23,023 shares of Avidity Biosciences worth $353K as of Q1 2023.
  • Kula Investments bought 5,065 Avidity Biosciences shares in Q1 2023, an estimated $111K.
  • Avidity Biosciences made up 0.09% of Kula Investments's portfolio in Q1 2023, its #411 holding.
  • Kula Investments first reported a position in Avidity Biosciences in Q4 2022 and has held it in 2 quarters since.
  • Kula Investments's Avidity Biosciences position peaked at $398K in Q4 2022.
  • 139 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.